Health Care·Biotechnology·$40.8B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.69 | N/A | -14.89% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-1.69 | N/A | -14.89% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about the current financial performance while reaffirming their commitment to long-term growth. They acknowledged the difficulties faced in the quarter.
Management highlighted ongoing challenges in achieving profitability.
They emphasized the need for continued investment in R&D despite losses.
Alnylam Pharmaceuticals reported a larger-than-expected loss per share, which contributed to a slight decline in stock price. The lack of revenue figures and guidance may indicate uncertainty about future performance. Investors may be cautious as the company navigates its financial challenges while focusing on research and development.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AMGEN INC
Feb 7, 2022